Stephanie Cape, PhD

Tiyash Bose, PhD

Dr. Tiyash Bose is a staff scientist at Labcorp Drug Development and has several years of research experience in bioanalytical method development. In his current role, Tiyash supports clinical trial studies by providing scientific and technical consultations to lab technicians, project managers and sponsors and oversees the laboratory's technical aspects to help ensure quality of the laboratory test results. Before joining Labcorp, Tiyash worked in the research and development division at Meridian Bioscience Inc.

Catherine Bor-Angelier, MD

Dr. Catherine Bor-Angelier joined Labcorp Drug Development in 2020. Prior to joining Labcorp, she was head of the pathology department in a French cancer center. Catherine led a European research program on breast cancer heterogeneity using mathematic tools. She has extensive experience in anatomic pathology of the breast, in gynecology and gastroenterology oncologic pathology, as well as molecular and integrative pathology.

Marion Bonnet, PhD

Dr. Marion Bonnet is a staff scientist in the histology department. In this role, Marion is responsible for validating new immunohistochemistry and in situ hybridization assays. She is also in charge of developing the immunofluorescent multiplexing platform. She works closely with clients to deliver assays that are fit for purpose and compliant with regulatory guidelines.

Nicolas Anfossi, PhD

Dr. Nicolas Anfossi is a global director of flow cytometry at Labcorp Central Laboratory Services since mid-2018. Labcorp Central Labs performs tests on samples from early to late phases of clinical development, generating data that will help characterize their safety and efficacy. In his current role, Nicolas supports the global operations of flow cytometry department at five global sites to ensure generation of reliable data and products, while keeping compliant with stringent regulations.

Labcorp Plasma Focus™ liquid biopsy test now available

Liquid biopsy tes t for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C. , May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted

Heart Failure: An underappreciated complication of diabetes

Results of a consensus report of the American Diabetes Association

Moderated by:

Renee Sullivan, MD, FACC
Rodica Pop-Busui, MD, PhD
Ambarish Pandey, MD, MSCS, FAHA

A mother's mission to save lives by raising preeclampsia awareness

For many, pregnancy can be a very special and personal milestone. It’s also a dynamic time: both mother and baby change and evolve daily. Anything involving rapid change also comes with the potential for complication. When it comes to pregnancy, one of the most dangerous complications is preeclampsia.Preeclampsia symptoms usually involve a mother’s blood pressure spiking to dangerous levels. This can lead to other complications—including seizure, stroke, multiple organ failure and death of the mother or baby. These complications can occur as early as 20 weeks—and in some rare cases—even earlier. However, when caught early, your healthcare provider team can help navigate preeclampsia and improve pregnancy outcomes.Theresa Dunn was diagnosed with preeclampsia near the end of her first pregnancy and then again during her second pregnancy. She knows firsthand how vital it is to understand the symptoms and advocate for yourself during pregnancy. This is why she’s passionate about sharing her preeclampsia experience to empower, advocate and educate.

Optimizing the strategic value of your lab: Q&A with Noel Maring

Noel Maring, executive director of health systems at Labcorp, answers questions healthcare executives may have around optimizing the strategic value of their lab.